COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN IN THE TREATMENT OF INVASIVE CANDIDA INFECTION IN CHINA

被引：0
|
作者：
Wang, C. [1 ]
Dong, H. [1 ]
Sun, L. [1 ]
机构：
[1] Shenyang Pharmaceut Univ, Shenyang, Peoples R China
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1604
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN61
引用
收藏
页码：A275 / A276
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION (CNV) IN CHINA
    Zhang, L.
    Lin, Z.
    Zhang, W.
    Xuan, J.
    VALUE IN HEALTH, 2019, 22 : S886 - S886
  • [42] Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China
    Wang, Zhenhua
    Sun, Ruixiaotong
    Sheng, Yanan
    Qu, Shuli
    Dong, Lu
    Wu, Bin
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (08)
  • [43] COST-EFFECTIVENESS ANALYSIS OF STANDARD PROPHYLAXIS VERSUS ON-DEMAND TREATMENT IN SEVERE HEMOPHILIA A IN CHINA
    Fang, H.
    Chen, C.
    Han, L.
    Wu, J.
    VALUE IN HEALTH, 2017, 20 (05) : A219 - A220
  • [44] Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
    Nathwani, Dilip
    Cornely, Oliver A.
    Van Engen, Anke K.
    Odufowora-Sita, Olatunji
    Retsa, Peny
    Odeyemi, Isaac A. O.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (11) : 2901 - 2912
  • [45] THE COST-EFFECTIVENESS ANALYSIS OF TWO PEGYLATED INTERFERON ALFA TREATMENT FOR CHRONIC HCV INFECTION IN CHINA
    Liu, G.
    Wei, L.
    Xu, F.
    Xu, Q.
    You, X.
    VALUE IN HEALTH, 2014, 17 (07) : A806 - A806
  • [46] COST-EFFECTIVENESS ANALYSIS OF VORICONAZOLE VERSUS AMPHOTERICIN B DEOXYCHOLATE IN THE TREATMENT OF INVASIVE PULMONARY ASPERGILLOSIS IN COLOMBIA
    Lemos, E., V
    Cortes, J.
    Gutierrez-Ardila, M., V
    Nunez, S. M.
    Prieto, H. A.
    VALUE IN HEALTH, 2012, 15 (04) : A243 - A243
  • [47] COST-EFFECTIVENESS ANALYSIS OF DIFFERENT TREATMENT STRATEGIES FOR SCHIZOPHRENIA IN CHINA
    Du, X. M.
    Huang, Y.
    VALUE IN HEALTH, 2023, 26 (06) : S126 - S126
  • [48] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN CHINA
    Zhang, Y.
    Yang, L.
    Dong, P.
    Xie, X.
    Tang, B.
    VALUE IN HEALTH, 2012, 15 (07) : A673 - A673
  • [49] COST-EFFECTIVENESS ANALYSIS OF FAMPRIDINE FOR MULTIPLE SCLEROSIS TREATMENT IN CHINA
    Zhao, X.
    Yang, H.
    Zhao, J.
    Wei, T.
    Liu, J.
    VALUE IN HEALTH, 2022, 25 (07) : S413 - S413
  • [50] Treatment for Severe Lupus Nephritis: A Cost-Effectiveness Analysis in China
    Dai, Zonglin
    Zhang, Xi
    Wong, Irene Ol
    Lau, Eric H. Y.
    Lin, Zhiming
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345